Skip to main content
Premium Trial:

Request an Annual Quote

Protagen, MicroDiscovery Collaborate on Biomarkers

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – German protein research firm Protagen this week said it and MicroDiscovery are collaborating to identify and validate biomarkers.

Protagen will use its UNIArray technology platform while MicroDiscovery will incorporate its software for the analysis of complex biomarker panels as part of the collaboration.

Terms of the deal were not disclosed.

Based in Dortmund, Protagen last month announced it had raised €10 million ($14 million) in a second financing round. In a statement this week, Peter Schulz-Knappe, CSO and executive vice president of diagnostics for Protagen said the deal with Berlin-based MicroDiscovery "strengthens our position in biomarker development and supports the efficient development of marketable products."

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.